Vivet Therapeutics, a clinical-stage biotech company specialising in the development of gene therapies, has announced that its co-founder and Chief Scientific Officer Dr Gloria Gonzalez-Aseguinolaza has been honoured with the Rosalind Franklin Society (RFS) Special Award in Science.
It was given by Mary Ann Liebert, and recognises Gloria’s contributions to advancing scientific knowledge.
The RFS Special Award is presented to one winner annually, and recognises the contribution of women or minority groups in science.
Rosalind Franklin, whose work was notably overlooked and undermined during her career, was instrumental in the discovery of the structure of DNA.
Therefore, the awards programme was developed to honour her name, while congratulating those who also contribute highly to the advancement of scientific knowledge.
Dr Gloria Gonzalez-Aseguinolaza, Co-Founder & Chief Scientific Officer at Vivet Therapeutics, said: “This is a tremendous honour, and I am very pleased that the RFS Society recognises my dedication and work in the field of gene therapy. Rosalind Franklin remains an inspiration to scientists around the world and I am delighted to be working with the team at Vivet to develop gene therapies with the potential to transform the lives of patients with inherited liver metabolic disorders.”